10.21
Schlusskurs vom Vortag:
$10.23
Offen:
$10.21
24-Stunden-Volumen:
20,799
Relative Volume:
1.90
Marktkapitalisierung:
$219.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Helix Acquisition Corp Iii Stock (HLXC) Company Profile
Firmenname
Helix Acquisition Corp Iii
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie HLXC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
HLXC
Helix Acquisition Corp Iii
|
10.21 | 219.92M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
9.44 | 2.75B | 3.13B | -174.20M | -111.20M | -0.6937 |
|
XXI
Twenty One Capital Inc
|
7.60 | 2.63B | 0 | 0 | 0 | 0.00 |
|
CCCX
Churchill Capital Corp X
|
13.50 | 804.69M | 0 | 0 | 0 | 0.00 |
|
DMII
Drugs Made In America Acquisition Ii Corp
|
9.97 | 653.13M | 0 | 0 | 0 | 0.00 |
|
CEPF
Cantor Equity Partners Iv Inc
|
10.47 | 597.79M | 0 | 0 | 0 | 0.00 |
Helix Acquisition Corp Iii Aktie (HLXC) Neueste Nachrichten
Helix Acquisition Corp. III completes $172.5 million IPO and private placement - Investing.com
Helix Acquisition Corp. III Completes Initial Public Offering - TradingView
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life - Citeline News & Insights
With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma - Institutional Investor
Helix Acquisition prices $150M initial public offering - MSN
Will Helix Acquisition Corp. II stock continue dividend increasesRate Cut & AI Forecast Swing Trade Picks - mfd.ru
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO By Investing.com - Investing.com Nigeria
Helix Acquisition Corp III closes $172.5 million IPO By Investing.com - Investing.com South Africa
Helix Acquisition Corp. III closes $172.5 million IPO By Investing.com - Investing.com Australia
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO - Investing.com
Helix Acquisition Corp. III closes $172.5 million IPO - Investing.com India
Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares - The Manila Times
SL Green Realty Corp. Announces Date of 2026 Annual Meeting of Stockholders - The Manila Times
White & Case advises Helix Acquisition Corp. III on upsized US$150 million IPO - White & Case LLP
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
Helix Acquisition III Raises $150 Million, Targets Healthcare Sector - Intellectia AI
Helix Acquisition Corp. III Prices Upsized $150 Mln IPO - Nasdaq
Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering - The Manila Times
Helix Acquisition III launches $150M healthcare-focused SPAC IPO - Stock Titan
Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC - Endpoints News
HLXC IPO NewsCormorant's SPAC Helix Acquisition III files for a $125 million IPO, targeting healthcare - renaissancecapital.com
BBOT Debuts as a Publicly Traded Company Focused on - GlobeNewswire
BridgeBio Oncology Lands Massive $382M SPAC Deal as Top Investors Back Cancer Drug Pipeline - Stock Titan
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal - BioSpace
Helix Acquisition Corp. II SEC 10-Q Report - TradingView
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
BridgeBio Oncology and Helix enter definitive merger agreement - Pharmaceutical Technology
BridgeBio spinout to go public in SPAC deal (HLXB:NASDAQ) - Seeking Alpha
Life Sciences Hedge Fund Perceptive Preps a New SPAC - Institutional Investor
Helix Acquisition Corp. II Closes of $184 Million IPO - citybiz
Helix Acquisition Corp. II Prices of Upsized $160 Million IPO - citybiz
Cormorant Launches Second SPAC Following MoonLake Deal with $100M IPO - BioSpace
MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab - Business Wire
Finanzdaten der Helix Acquisition Corp Iii-Aktie (HLXC)
Es liegen keine Finanzdaten für Helix Acquisition Corp Iii (HLXC) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):